CSF3 and neutropenia: In contrast, we saw no FN, grade 4 toxicity or treatment‐related death in the present study, even though primary prophylactic G‐CSF support and prophylactic antibiotics were not permitted, and use of secondary prophylactic G‐CSF against neutropenia (8.3%) was limited throughout the IC phase.